Dipeptidyl peptidase-4 inhibitor treatment could decreaseKlebsiella pneumoniaepneumonia in patients with type 2 diabetes

被引：1

作者：

Chen, Hsin-Hung ^{[1
,2
]}

Chen, Ching-Chu ^{[3
,4
]}

Ho, Chun-Wei ^{[1
]}

Hsieh, Ming-Chia ^{[1
,5
,6
]}

Hsu, Sheng-Pang ^{[3
]}

Lin, Cheng-Li ^{[7
,8
]}

Kao, Chia-Hung ^{[9
,10
,11
,12
,13
]}

机构：

[1] China Med Univ Hosp, Intelligent Diabet Metab & Exercise Ctr, Taichung, Taiwan

[2] Chung Shan Med Univ, Inst Med & Publ Hlth, Sch Med, Taichung, Taiwan

[3] China Med Univ Hosp, Dept Internal Med, Div Endocrinol & Metab, Taichung, Taiwan

[4] China Med Univ, Sch Chinese Med, Taichung, Taiwan

[5] China Med Univ, Grad Inst Integrat Med, Taichung, Taiwan

[6] China Med Univ Hosp, Div Clin Nutr, Taichung, Taiwan

[7] China Med Univ Hosp, Management Off Hlth Data, Taichung, Taiwan

[8] China Med Univ, Coll Med, Taichung, Taiwan

[9] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan

[10] China Med Univ Hosp, Dept Nucl Med, Taichung, Taiwan

[11] China Med Univ Hosp, PET Ctr, Taichung, Taiwan

[12] Asia Univ, Dept Bioinformat & Med Engn, Taichung, Taiwan

[13] China Med Univ Hosp, Ctr Augmented Intelligence Healthcare, Taichung, Taiwan

来源：

POSTGRADUATE MEDICINE | 2020年 / 132卷 / 08期

关键词：

Dipeptidyl peptidase-4 inhibitor (DPP4i); klebsiella pneumoniae (KP); diabetes; cohort study; KLEBSIELLA-PNEUMONIAE; GLYCEMIC CONTROL; RISK-FACTORS; MELLITUS; VILDAGLIPTIN; ASSOCIATION; INFECTIONS; BACTEREMIA;

D O I：

10.1080/00325481.2020.1793520

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives To investigate the effect of dipeptidyl peptidase-4 inhibitor (DPP4i) forKlebsiella pneumoniae(KP) pneumonia in patients with diabetes. Patients and methods Patients newly diagnosed with type 2 diabetes from 2009 to 2012 were recruited for this population-based and observational study. Diabetes complications severity index (DCSI) score and defined daily dose (DDD) were used for analysis. The multivariable Cox proportional hazards models were used to estimate the risk of KP pneumonia by DPP4i use, with adjustments for propensity score. The Kaplan-Meier method with the log-rank test was used to estimate the risk of KP pneumonia for DPP4i users. Results 34774 patients were included. The incidence rate of KP pneumonia in DDP4i users was 1.51 per 1000 person-years and that for the comparison was 2.25 per 1000 person-years. DDP4i users also had a significantly lower cumulative incidence of KP pneumonia (log-rank test p-value = 0.03). DDP4i users had a significantly lower risk of developing KP pneumonia compared with nonusers (adjusted HR = 0.67, 95% CI = 0.48-0.95). Conclusions For public health issue with type2 diabetes and infection, DPP4i use decreased KP pneumonia. Male gender, patients with co-morbidities, patients with higher DSCI score and higher DDD of DPP4i were observed to decrease KP pneumonia infection in our analysis. The possible role of DPP4i causing immunological disturbances should be considered.

引用

页码：714 / 719

页数：6

共 44 条

[1]

[Anonymous], 2014, J AM PODIATR MED ASS, DOI DOI 10.7547/13-026.1

[2]

[Anonymous], 2017, NIH PUBL

[3] Airway Glucose Homeostasis A New Target in the Prevention and Treatment of Pulmonary Infection [J].